Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What is your approach to managing ILD associated with inflammatory bowel disease?
Related Questions
How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
What immunosuppression regimens do clinicians use in patients with progressive RB-ILD despite smoking cessation and prednisone?
